Istradefylline 40 mg + Istradefylline 20 mg + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Parkinson's Disease
Conditions
Idiopathic Parkinson's Disease
Trial Timeline
Oct 1, 2013 → Oct 1, 2016
NCT ID
NCT01968031About Istradefylline 40 mg + Istradefylline 20 mg + Placebo
Istradefylline 40 mg + Istradefylline 20 mg + Placebo is a phase 3 stage product being developed by Kyowa Kirin for Idiopathic Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01968031. Target conditions include Idiopathic Parkinson's Disease.
What happened to similar drugs?
20 of 20 similar drugs in Idiopathic Parkinson's Disease were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01968031 | Phase 3 | Completed |
Competing Products
20 competing products in Idiopathic Parkinson's Disease